These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-002183-18 ESOPE (QLK3-2002-02003) European Standard Operating Procedures for Electrochemotherapy and Electrogenetherapy not-yet-due
Listed as ongoing, but also has a completion date 2006-001065-41 Phase 2 single-arm studies of Gemcitabine in combination with Oxaliplatin in refractory and relapsed pediatric solid tumors 2009-04-20 bad-data
Ongoing 2006-001067-39 Etude de phase II de l'association 5-fluoro-uracile - acide folinique (schéma LV5FU2 simplifié) et cetuximab en intraveineux avec une chimiothérapie intra-artérielle hépatique par Oxaliplatine dans le... not-yet-due
Exempt 2007-000527-18 Monocentric, open label, uncontrolled phase I-II study to evaluate the safety and the maximum tolerated dose of sorafenib given daily in combination with temozolomide (extended schedule) in patients w... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-001200-20 A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer 2010-07-27 bad-data
Listed as ongoing, but also has a completion date 2008-001436-12 Estudio Fase II no aleatorizado de tratamiento con Temozolamida combinada con Topotecan para neuroblastoma y otros tumores sólidos pediátricos en situación de recaída o progresión. "Phase 2 single-arm... 2011-07-04 bad-data
Ongoing 2008-002159-25 Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement not-yet-due
Ongoing 2008-007412-15 Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine gyn... not-yet-due
Not reported 2009-012430-70 Etude de phase II multicentrique étudiant l’efficacité de la doxorubicine associée à de la trabectedine (Yondelis) en première ligne dans le traitement des patients présentant un léiomyosarcome métas... 2016-10-12 due-trials
Completed, but no date 2009-015598-11 Essai de phase III multicentrique comparant la surveillance simple (standard) à la laparotomie exploratrice plus chimio-hyperthermie intrapéritonéale (CHIP), chez des patients atteints d’un cancer col... bad-data
Not reported 2009-017000-83 Essai de phase II évaluant l’effet curatif de la pravastatine chez des patients présentant une fibrose cutanée et sous-cutanée radio-induite établie 2018-04-18 due-trials
Ongoing 2009-017047-34 Essai de phase 2-3 randomisé, comparant deux modalités de réirradiation après chirurgie en territoire irradié des carcinomes des voies aéro-digestives supérieures : - radiothérapie monofractionnée av... not-yet-due
Listed as ongoing, but also has a completion date 2010-019224-31 INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS 2023-12-29 bad-data
Ongoing 2010-024621-20 First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma not-yet-due
Listed as ongoing, but also has a completion date 2012-003005-10 PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA 2021-04-25 bad-data
Exempt 2012-004842-14 PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA not-yet-due
Ongoing 2013-000286-36 A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors Etude de phase II prospective évaluant le cabazitaxel chez de... not-yet-due
Ongoing 2014-001929-32 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication not-yet-due
Ongoing 2014-005586-75 A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer Ensayo clínico fase II aleatorizado d... not-yet-due
Listed as ongoing, but also has a completion date 2015-003130-27 An international multicenter phase II randomised trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemoth... 2023-07-03 bad-data
Other 2015-005464-42 A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours Ensayo c... not-yet-due
Exempt 2016-000133-40 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors not-yet-due
Ongoing, reported early 2016-002186-56 Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in patien... not-yet-due
Other 2017-000741-46 RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS not-yet-due
Completed, but no date 2017-000742-21 Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RA... bad-data
Other 2017-001277-17 Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and... not-yet-due
Ongoing 2017-001606-14 A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer Etude de préférence des patients entre l’ODM-201 et l’Enzalutamide chez des ... not-yet-due
Other 2017-001628-23 Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable head... not-yet-due
Other 2017-003622-33 Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer Etude de Phase II randomisée évaluant... not-yet-due
Other 2017-004639-35 A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer Etude de phase III évaluant l’impact sur la survie de l’acide acétylsalicylique et l’... not-yet-due
Other 2018-000515-24 An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Uno studio globale su bambini e adulti con RabdoMioSarcoma frontline e recidivante not-yet-due
Ongoing 2018-001447-31 Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolida... not-yet-due
Completed, but no date 2018-001744-62 A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-d... bad-data
Exempt 2018-002688-24 Phase I-II study of nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma not-yet-due
Ongoing 2018-003115-21 A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors not-yet-due
Other 2019-001068-31 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic pha... not-yet-due
Other 2019-002442-20 Study evaluating near infrared imaging coupled with indocyanine green for preoperative control of resection margins in ENT surgery. Etude évaluant l'imagerie proche infrarouge couplée au vert d'ind... not-yet-due
Completed, but no date 2019-002507-18 Efficacy and feasibility of pasireotide to reduce clinically relevant digestive leakage after complete cytoreductive surgery (CRS) plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for peritonea... bad-data
Exempt 2020-000825-18 An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed plat... not-yet-due
Not reported 2020-001250-21 COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients 2021-06-10 due-trials
Other 2020-002766-14 An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors not-yet-due
Other 2020-004696-41 Randomized Preoperative Breast Immune Selection (BIS) Program in patients with early breast cancer not-yet-due
Other 2020-005722-28 Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to t... not-yet-due
Other 2020-005723-37 Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to charac... not-yet-due
Other 2020-006106-23 Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients not-yet-due
Other 2021-006638-38 A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06) not-yet-due
Other 2021-006795-16 Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study- PULSE not-yet-due
Other 2021-006958-31 An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C not-yet-due
Exempt 2022-002874-10 Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma not-yet-due